Collegium Pharmaceutical, Inc. Common Stock

Collegium Pharmaceutical announced the award of 50,305 restricted stock units (RSUs) to 34 newly hired non-executive employees on June 1, 2026, as material inducement for employment. The RSUs will vest over a three-year period with one-third vesting on June 10, 2027, followed by equal annual installments, subject to continued service.

Collegium Pharmaceutical announced its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026. The company, which specializes in CNS and pain management medications, recently completed the acquisition of AZSTARYS and reported Q1 2026 net revenues of $193.5 million, up 9% year-over-year, w...

Collegium Pharmaceutical completed its acquisition of AZSTARYS, an ADHD treatment, from Corium Therapeutics for approximately $650 million. The acquisition is expected to be immediately accretive and includes patent protection through 2037. Collegium raised its 2026 financial guidance, projecting total product revenues of $865-$895 million and ad...

Collegium Pharmaceutical's General Counsel David Dieter sold 6,224 shares (6.4% of his holdings) for $228,110 under a pre-planned trading arrangement. The sale is modest and non-discretionary, but the real story is Collegium's strategic pivot toward ADHD treatments, with Jornay PM growing 48% in its first full year and the company acquiring AZSTA...

Collegium Pharmaceutical announced it will present two posters featuring real-world data from its pain medication portfolio at the American Academy of Pain Medicine's Annual Meeting in Salt Lake City (March 5-8, 2026). The presentations will highlight clinical insights on BELBUCA (buprenorphine buccal film) and its performance compared to other o...